You just read:

Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis

News provided by

Eli Lilly and Company

Apr 22, 2019, 06:45 ET